Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women

Phase 2

• Conditions: Alopecia

• Registration Number: NCT00418249
• Lead Sponsor: Rabin Medical Center

Brief Summary

The primary objective of this study is to assess the safety and efficacy of topical AS101 as treatment for Female Androgenetic Alopecia (FAGA) in menopause women.

Detailed Description

Not available

Study Timeline

• Status Verified: 2006-12
• Study First Submitted: 2007-01-02
• Study First Submitted QC: 2007-01-03
• Last Update Submitted: 2007-01-03
• Study First Posted: 2007-01-04
• Last Update Posted: 2007-01-04

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

• Women in menopause, over 50 years of age.
• Clinically diagnosed for AGA, according to Ludwig scale I-II.

Exclusion Criteria

• Women treated with chronic medications.
• Use of Minoxidil within 3 months prior to entering study.
• Women who have underwent hair transplantation.
• Use of drugs with androgenic or anti-androgenic effects.
• Any other type of hair loss.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
hair density

Secondary Outcome Measures

Name	Time	Method
Self-administered satisfaction questionnaire
Hair diameter, anagen/telogen ratio and hair growth rate,Global photographic assessment according to Female-Ludwig scale,